Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Imatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 20/20 | 0.97 |
| ▸ | BCR known ✓ | P11274 | 14/20 | 0.97 |
| ▸ | KIT known ✓ | P10721 | 12/20 | 0.97 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.94 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.97 |
| ▸ | RAD52 | P43351 | 1/20 | 0.97 |
| ▸ | ABL2 | P42684 | 7/20 | 0.94 |
| ▸ | LYN | P07948 | 3/20 | 0.94 |
| ▸ | SRC | P12931 | 2/20 | 0.94 |
| ▸ | SYK | P43405 | 2/20 | 0.94 |
| ▸ | PLK4 | O00444 | 1/20 | 0.94 |
| ▸ | DDX3X | O00571 | 1/20 | 0.94 |
| ▸ | GAK | O14976 | 1/20 | 0.94 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.94 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.94 |
| ▸ | CA12 | O43570 | 1/20 | 0.94 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.94 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.94 |
| ▸ | EGFR | P00533 | 1/20 | 0.94 |
| ▸ | CA1 | P00915 | 1/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imatinib SCHEMBL726190 | 0.99 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL1060852 | 0.99 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL8217 | 0.99 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL29370699 | 0.99 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL15632914 | 0.99 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL1673189 | 0.99 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL29377238 | 0.99 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL1440465 | 0.98 | ABL1 (0.99) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL1439360 | 0.98 | ABL1 (0.99) | ABL1BCRKITPDGFRARAD52 | |
| Imatinib SCHEMBL2236091 | 0.97 | ABL1 (1.00) | ABL1BCRKITPDGFRARAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2787977-A1 | LIPOSOMAL DRUG ENCAPSULATION | The Regents of The University of California (US) | 2014-10-15 | — | — | EP | claimed |
| WO-2013086526-A1 | LIPOSOMAL DRUG ENCAPSULATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-06-13 | — | — | WO | claimed |
| US-20120142697-A1 | Salt forms of 4-(4-Methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino)phenyl]-benzamide | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | claimed |
| US-20080249104-A1 | such as imatinib ascorbate, imatinib formate, imatinib malonate, imatinib oxaloacetate, imatinib squarate and imatinib vanillate; treatment of a tumour disease, especially the treatment of leukemia | BURGER HANS MICHAEL | 2008-10-09 | — | — | US | claimed |
| EP-1713792-A2 | SALT FORMS OF 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-n- 4-METHYL-3 -(4-PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO)PHENYL -BENZAMIDE | Novartis AG (CH) | 2006-10-25 | — | — | EP | claimed |
| WO-2005075454-A2 | SALT FORMS OF 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-n-[4-METHYL-3-(4-PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO)PHENYL]-BENZAMIDE | NOVARTIS AG (CH) | 2005-08-18 | — | — | WO | claimed |
| US-20140356416-A1 | LIPOSOMAL DRUG ENCAPSULATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-12-04 | — | — | US | disclosed |
| EP-2787977-A1 | LIPOSOMAL DRUG ENCAPSULATION | The Regents of The University of California (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20140051853-A1 | Salt forms of 4-(4-Methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| US-8513256-B2 | Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | NOVARTIS AG (CH) | 2013-08-20 | — | — | US | disclosed |
| WO-2013086526-A1 | LIPOSOMAL DRUG ENCAPSULATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-06-13 | — | — | WO | disclosed |
| US-20120142697-A1 | Salt forms of 4-(4-Methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino)phenyl]-benzamide | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-20080249104-A1 | such as imatinib ascorbate, imatinib formate, imatinib malonate, imatinib oxaloacetate, imatinib squarate and imatinib vanillate; treatment of a tumour disease, especially the treatment of leukemia | BURGER HANS MICHAEL | 2008-10-09 | — | — | US | disclosed |
| EP-1713792-A2 | SALT FORMS OF 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-n- 4-METHYL-3 -(4-PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO)PHENYL -BENZAMIDE | Novartis AG (CH) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005075454-A2 | SALT FORMS OF 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-n-[4-METHYL-3-(4-PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO)PHENYL]-BENZAMIDE | NOVARTIS AG (CH) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140356416-A1 | LIPOSOMAL DRUG ENCAPSULATION | LIPA, NSF, LIPG | ABL1 2741/4885BCR 931/4885KIT 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.